Dr. ir. C.E. Charlotte Teunissen
VU University Medical Center
PRODIA: Development of biomarkers enabling early and accurate differential diagnosis of dementia
The overall aim of this project is to improve patient care by developing early CSF biomarkers for dementia subtypes with a proven relation to pathology. This aim has the following objectives: 1) Expansion and integration of the current proteomic databases for optimal candidate biomarker selection. We will expand the databases with tissue proteomics results of FTD patients. 2) Full development of immunoassays for 3 candidates in CSF. We will employ state-of-the-art and extremely sensitive technologies for a first test if the biomarkers can be measured in blood as well. 3) Clinical validation of candidate biomarkers (3 from WP2, plus 1 existing assays) in CSF of well-characterized, multi-center patient cohorts consisting of patients with different types of dementia. 4) We will establish the relation of the candidate biomarkers with the evolution progression of the specific disease pathology in-detail for each of the dementias. Therefore, we will study the expression of the validated candidate biomarkers from WPs1-3 in tissue of dementia patients and relevant controls.